Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 11, 2008
Increased use of Zevalin, Bayer ( & by osmosis Bexxar, GSK) in low grade lymphomas
Analysis of: Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma | jco.ascopubs.org
Author: GLG Expert Contributor
Addition of Zevalin after a CR or PR in low grade, follicular lymphomas adds to CR rates and improves time to progression. The implication is that this will result in improved survivals.
November 10, 2008
Big Pharma will continue to thrive in new administration, but not insurnace companies
Analysis of: Pharma need not worry too much about President Obama | www.pharmatimes.com
Author: GLG Expert Contributor
President elect Obama will try , most probably unsuccessfully, to take on insurance companies in orfder to fulfill his election promises of "close to universal" health care. Generics will thrive, but Big Phrama , especially those with innovative products and biotech companies will continue to pr...
November 10, 2008
Rainfall unlikely to be direct culprit to the Autism Pandemic
Analysis of: Autism linked with rainfall in study | www.boston.com
Author: GLG Expert Contributor
A recent study infers taht periods of increased rainfall could be linked to increase in number of children dioagnosed with autism. The causla l;ink of rainfall is unlikely, but most probably reflects other factors like children staying more indoors and thus watch more TV, get less sun exposure and...
November 10, 2008
Avastin for GBM: modest efficacy and soon to be approval
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Genetech's Avastin have shown modest increase in progresion free survival and overall survival in patients with gliobalstoma multiforme, the most common and most agressive malignant brain tumor With such data, Avastin is expected to join Temodar as chemotherapy agent approved for this tumor with...
November 10, 2008
Is Pharma's Head in the Sand??
Analysis of: Pharma need not worry too much about President Obama | www.pharmatimes.com
Author: GLG Expert Contributor
The implication is that our new chief executive has "bigger fish to fry" than attaching drug costs??
November 10, 2008
Avastin Likely To Be Rapidly Adopted for Treatment of Glioblastoma
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Glioblastoma (GBM) is a terrible diease with little chance of long term survival and few advancements in over the last few decades. While the recent study of Avastin in GBM was not a definitive study, data presented in the press release suggest that Avastin has clear activity in relapsed GBM...
November 6, 2008
GSK to cut sales force , but......
Analysis of: Glaxo Plans 12% Reduction in Its U.S. Drug Sales Force | online.wsj.com
Author: GLG Expert Contributor
"As part of the restructuring, the company plans to group its sales staff around specific treatment areas" including oncology, probably
November 6, 2008
Avastin in Glioblastomas: I believe approval will be....
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Genetech is seeking FDA approval for use in the most malignant of brain tumors, Glioblastomas.
November 3, 2008
Apidra for Diabetes: No much innovation but will get some use
Analysis of: FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes | www.pipelinereview.com
Author: GLG Expert Contributor
Sanofi's rapid acting insulin formulation got FDA approval for use in children 4 years and older with Type I insulin dependent diabetes. The drug has rapid action so it may replace lispro and older short acting  insulin preparations, if the price tag is not prohibitive.
October 28, 2008
Yes, Smaller Populations for Targeted drugs, but Pharma/Biotech AND Patients Win
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: GLG Expert Contributor
While targeting a drug to the right patients may in fact the decrease the size of the patient population for that drug, but several factors may actually result in benefit not only for patients, but for biotech/pharma companies, insurance companies and society.   When a drug is given...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 1055

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617